Browse Projects
Number of Projects: 3

23 Downloadable Samples



Bulk RNA-seq

DiagnosisAnaplastic astrocytoma (1), Anaplastic glioma (1), Diffuse midline glioma (1), Glioblastoma (16), High-grade glioma (2), Non-cancerous (1), Pleomorphic xanthoastrocytoma (1)

Pediatric brain tumors are now the most common cause of mortality from disease in childhood. Molecular characteristics of pediatric high- and low-grade gliomas (PHGG and PLGG), the most common tumor category overall, are crucial to treatment and outcomes, but the impact of these characteristics and of the variety of cell populations in these tumors is poorly understood. We performed single-cell RNA-sequencing on viably banked single cell samples of high- and low- grade glial tumors from children treated at Children’s Hospital Colorado. These samples are part of ongoing single-cell pediatric brain tumor banking that our group initiated a decade ago. The maturity of this resource, collected over a decade, provides us with the opportunity to perform well-powered outcome association studies. Samples are collected during routine surgery and immediately disaggregated to isolate single cells. These are then viably frozen in DMSO and banked for later use. We have tumors that cover the variety of subtypes in each of these diseases, as well as comprehensive clinical information on these cases, which will allow us to correlate molecular subtypes and research findings with these clinical measures. Here, we perform single-cell RNA-sequencing on 23 samples from patients with PHGG. In PHGG, we aim to understand the extent to which pediatric HGG stem like cells may differentiate into other cell types found in HGG tumors, or whether the non-stemlike cells may be derived from host tissue; whether gene expression is altered in host cells as the result of interactions with tumor stem cells; and the extent to which specific gene expression patterns among tumor cell subpopulations correlate with outcome measures such as mortality or event-free survival. These studies will significantly advance our understanding of disease biology and provide the detailed molecular and functional insights needed to identify new therapeutic targets for these biologically and clinically heterogeneous tumors.

DeSisto J., A. M. Donson, A. M. Griesinger, R. Fu, K. Riemondy, et al., 2023 Tumor and immune cell types interact to produce heterogeneous phenotypes of pediatric high-grade glioma. Neuro-oncology 26: 538-552.
Also deposited underSRP436316, SRP436322, GSE231858, GSE231859
Additional Sample Metadata Fieldsdevelopment_stage_ontology_term_id, disease_ontology_term_id, molecular_characteristics, organism, organism_ontology_id, outcome, participant_id, self_reported_ethnicity_ontology_term_id, sex_ontology_term_id, spinal_leptomeningeal_mets, submitter, submitter_id, tissue_ontology_term_id

38 Downloadable Samples



Bulk RNA-seq, Multiplexed

34 samples are multiplexed. Learn more

DiagnosisAnaplastic ependymoma (4), Anaplastic ganglioglioma (1), Desmoplastic ganglioglioma (2), Dysembryoplastic neuroepithelial tumor (3), Dysplastic gangliocytoma (1), Ependymoma (5), Ganglioglioma (1), Glioblastoma (1), Low-grade glioma (1), Medulloblastoma (4), Myxopapillary ependymoma (1), Non-cancerous (3), Pilocytic astrocytoma (6), Pilomyxoid astrocytoma (1), Primitive neuroectodermal tumor (3), Schwannoma (1), Subependymoma (1)

Single cell gene expression profiling of pediatric central nervous system (CNS) tumors holds great potential to further our understanding of carcinogenesis, augment prognostic indicators, and identify rational therapeutic targets. Whereas the genomic characteristics of these tumors are fairly well-defined in aggregate, the extent to which cellular heterogeneity is associated with carcinogenesis and clinical outcomes is largely unknown. Here we profile single nuclei gene expression in 36 brain tumor specimens from individuals with a diagnosis of ependymoma, glioma, or embryonal CNS tumor with substantial follow up time, as well as non-tumor brain tissue from three pediatric controls. We used the 10X Genomics Single Cell platform to obtain single nuclei for RNA sequencing in conjunction with bulk RNA sequencing. In conjunction with this study, we obtained 5-methyl- and 5-hydroxymethylation profiles on these samples to investigate functional aspects of gene regulation by cytosine modification. The data and results from this study are expected to reveal an abundance of information about pediatric CNS tumors with value for the broader scientific community.

Lee M. K., N. Azizgolshani, J. A. Shapiro, L. Nguyen, F. K. IV, et al., 2024 Identifying tumor type and cell type-specific gene expression alterations in pediatric central nervous system tumors. Nat Commun 15: 3634.
Lee M. K., N. Azizgolshani, Z. Zhang, L. Perreard, F. K. IV, et al., 2024 Associations in cell type-specific hydroxymethylation and transcriptional alterations of pediatric central nervous system tumors. Nat Commun 15: 3635.
Also deposited underSRP392501, GSE211362
Additional Sample Metadata FieldsDeveloped_recurrence, development_stage_ontology_term_id, disease_ontology_term_id, location_class, organism, organism_ontology_id, participant_id, self_reported_ethnicity_ontology_term_id, sex_ontology_term_id, submitter, submitter_id, tissue_ontology_term_id, WHO_grade, Years_to_recurrence

15 Downloadable Samples



DiagnosisDiffuse midline glioma (2), Glioblastoma (3), High-grade glioma (7), Infant-type hemispheric glioma (3)

Pediatric tumors are rare and deadly diseases, currently the leading cause of disease related death in children (Ped), adolescent and young adults (AYA) - Ped-AYA. Gliomas are the most common brain tumor in the Ped-AYA group and malignant high-grade glial lesions remain incurable. The most underserved and understudied group for that disease are the older children, the adolescent group and young adults ranging in age between 15 to 39. Historically, gliomas were explored within two groups: pediatric and adults and AYA glioma were analyzed as a fraction of the adult's population study while patients were distributed through pediatric and adult hospital due to undefined age-related intervention. We identified the unmet need to explore the pediatric population with the AYA age group as these were never studied together. We utilized Ped-AYA HGG samples from the Children's Brain Tumor Network (CBTN). This cohort represents 15 tumor events obtained from 9 patients, with a mix of primary-progression and progression-recurrent tumor pairs. Matched tumor/normal WGS or tumor WGS, tumor RNA-Seq, methylation, and proteogenomics data are available from this cohort through

PublicationsNot Specified
Also deposited underNot Specified
Additional Sample Metadata Fieldsage_at_chemo_start, age_at_event_days, age_at_radiation_start, age_last_update_days, cancer_group, cancer_predispositions, clinical_status_at_event, CNS_region, development_stage_ontology_term_id, disease_ontology_term_id, EFS_days, EFS_event_type, ethnicity, extent_of_tumor_resection, external_aliquot_id, external_run_id, mutation_status, organism, organism_ontology_id, OS_days, OS_status, participant_id, pathology_free_text_diagnosis, race, self_reported_ethnicity_ontology_term_id, sex_ontology_term_id, submitter, submitter_id, tissue_ontology_term_id
Alex’s Lemonade Stand Foundation for Childhood Cancer333 E. Lancaster Ave, #414, Wynnewood, PA 19096 USAPhone: 866.333.1213 • Fax: 610.649.3038Email: